First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients

Leukemia Research
Pier Paolo PiccalugaMichele Baccarani

Abstract

Gemtuzumab ozogamicin (GO), an anti-CD33 monoclonal antibody conjugated to calicheamicin, is effective as single agent in the treatment of poor risk acute myeloid leukaemia (AML) patients. We treated with GO in combination with cytarabine as continuous perfusion nine elderly AML patients, either untreated (five cases), or with relapsed/refractory disease (four cases). Five patients achieved a complete remission (CR), four were resistant. One patient died while in CR due to CNS haemorrhage, two relapsed and two are still in CR. The median CR duration was 10 months. The median overall survival was 6 months (1-19 months). The most common adverse event was myelosuppression, as expected. No hepatic veno-occlusive disease was recorded. Notably, in four cases we observed a grade III/IV bleeding, including gasto-intestinal bleeding, epistaxis, CNS haemorrhage, and ocular bleeding. Larger prospective studies are now warranted in order to better define the possible role of this regimen in the treatment of elderly AML patients.

Citations

May 28, 2013·International Journal of Hematology·Akihiro Takeshita
Mar 30, 2007·Nature Clinical Practice. Oncology·Alejandro D Ricart, Anthony W Tolcher
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O Dillman
Aug 4, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·U BrunnbergW E Berdel
Mar 21, 2008·Expert Opinion on Biological Therapy·Roberto Stasi
Aug 4, 2011·Expert Opinion on Biological Therapy·Marie-Luise Hütter, Richard F Schlenk
Mar 25, 2006·Expert Opinion on Pharmacotherapy·Pier Paolo PiccalugaMichele Baccarani
Apr 22, 2009·Cancer Genetics and Cytogenetics·Antoine HarbMeir Wetzler
Apr 28, 2009·Surgical Oncology·Slavica KvolikLjubica Glavas-Obrovac
Aug 12, 2008·Seminars in Oncology·Hervé DombretClaude Gardin
Oct 19, 2007·Cancer Treatment Reviews·Roberto StasiSergio Amadori
Apr 3, 2008·Seminars in Hematology·Deborah Mulford
Nov 6, 2015·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Joshua Seth EatonChristopher J Murphy
Feb 15, 2011·British Journal of Haematology·Daniel A PollyeaBruno C Medeiros
Nov 30, 2010·Best Practice & Research. Clinical Haematology·Edward D Ball, H Elizabeth Broome

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.